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Infectious diseases account for ~20% of global mortality, and viruses are responsible for about one third of these deaths. 1 Lower respiratory infections and Human Immunodeficiency Virus (HIV) are among the first ten causes of deaths worldwide, and they contribute substantially to healthcare costs. 2 Emerging viruses (e.g. Ebola) add yearly to this death toll. The best approach to prevent viral infections is vaccination, however there exist only a limited number of vaccines and the ones that exist are not equally available in all parts of the world. 3 After infection, antiviral drugs are the only treatment option, but even in this case there are only a limited number of approved antiviral drugs and they are all virus specific. There is a dire need for broad-spectrum antiviral drugs that can act on a large number of existing and emerging viruses.
Current therapeutics can be subdivided into i) small molecules (e.g. nucleoside analogues and peptidomimetics), ii) proteins able to stimulate the immune response (e.g. interferon), and iii) oligonucleotides (e.g. fomivirsen). 4 They are mainly directed against HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), human cytomegalovirus (HCMV) and influenza virus. They act intracellularly, mostly on viral enzymes that are essential for viral replication but differ from any other host enzyme to allow for selectivity. Since viruses largely depend on the biosynthetic machinery of infected cells for their replication the specificity of antiviral drugs is far from ideal, resulting in a general intrinsic toxicity associated with such treatment. 5, 6 Additionally, most viruses mutate rapidly due to error-prone replication machinery, therefore they often develop resistance. 7 Finally, the use of virus specific proteins as a target of antiviral drugs makes it difficult to develop broad-spectrum antivirals capable of acting on a large number of viruses that are phylogenetically unrelated and structurally different.
Virustatic substances act outside the cell by interfering with the first phases of the viral replication cycle. They can be broad spectrum and non-toxic. Their activity depends on a reversible binding event; the reversibility of the mechanism makes them medically irrelevant.
For example, upon dilution the substance is detached from an unaltered viral particle allowing the virus to infect again. To achieve broad-spectrum efficacy, current virustatic materials (e.g.
heparin, polyanions) target virus-cell interactions that are common to many viruses. One of these interactions is that between the VAL and its associated cell receptor responsible for the first step constitute the VAL, with the negatively charged sulfated groups of heparan sulfate (HS) in the glycocalix of the cell surface. 9 A long list of HSPG mimicking materials such as heparin, 10, 11 sulfated polysaccharides, 9, 12 or sulfonic acid decorated polymers, dendrimers, and nanoparticles [13] [14] [15] [16] [17] have been tested and shown to exert potent virustatic activity in vitro, none have shown efficacy in humans. The only three polyanionic anti-HIV-1 microbicides that reached phase III clinical trial (i.e. polysulfonated PRO2000, the polysulfated Carraguard, and cellulose sulfate Ushercell) did not prevent vaginal HIV-1 transmission and in some cases even increased the rate of infection. [18] [19] [20] [21] One of the possible explanations is that their effect was simply virustatic and hence vaginal and seminal fluids lead to the dilution of both the viruses and the active compounds, which resulted in the complete loss of binding and release of active virus.
Arguably, the ideal drug against a viral infection would be virucidal. Virucidal molecules cause irreversible viral deactivation, indeed their effect is retained even if dilution occurs after the initial interaction with the virus. 22 There is a vast literature on many virucidal materials ranging from simple detergents, to strong acids, or more refined polymers, 23 and nanoparticles (NPs) [24] [25] [26] [27] that, in some cases, are capable of releasing ions. 28, 29 In all cases, the approaches utilized have intrinsic cellular toxicity. 26 Indeed, all of these materials attempt to chemically damage the virus, but it is a tall order to selectively damage a virus without affecting the host the virus replicates within.
An ideal drug should have all the positive properties of virustatic drugs such as broadspectrum efficacy and low toxicity, and at the same time show a virucidal mechanism. In this paper, we show that it is possible to change the mechanism of inhibition of an antiviral nanoparticle from virustatic to virucidal by engineering its linkers in a way that we hypothesize leads to multivalent binding (i.e. the binding of multiple targets at the same time) with the consequent generation of irreversible local distortion as schematically illustrated in Figure 1A . 
Virus and Nanoparticles Description
To evaluate the inhibitory activity of our nanoparticles (NPs) we used the following and resistant to protein non-specific adsorption version of MUS-coated gold particles that we have studied. [33] [34] [35] [36] All used NPs are summarized in Table 1 , and all synthetic methods and characterizations are presented in the supplementary information (SI) (Methods Section and
Supplementary Figures 1 to 7).

Viral Inhibition
Each virus was pre-incubated with different doses of gold NPs for 1 h at 37°C and 5% CO 2 ; then the mixture was added to the cell culture (see Methods Section in SI for virus-specific protocol details, initial viral load, and cell types), and infectivity was tested 24-72 h post infection. For the GFP expressing viruses (LV-VSV-G, AD-5 and HPV-16) the infectivity was quantified by flow cytometry, while plaque assays were used for wild-type viruses. Table 2 summarizes the results. It is noteworthy that the MUS functionalized NPs i) are indeed non-toxic at these concentrations showing favourable selectivity indexes, ii) are able to inhibit infection selectively for HSPG dependent viruses (i.e. no inhibition is observed for AD5), and that iii) all experiments aimed at establishing that the particles actually do target the HSPG seeking VAL.
Virucidal Results
As explained above, other sulfonated materials [16] [17] [18] [19] have also shown similar inhibitory effects as shown for MUS-NPs in Table 2 , but these effects have been proven 10, 11 or are assumed 33 to be virustatic and hence due to reversible attachment alone. To test whether a different inhibition mechanism was in place for our particles, we first verified the ability of our
NPs to inhibit viral attachment, as is known for heparin (Supplementary Figure 9) . Then, we verified the ability of MUS:OT-NPs, MES-NPs, and heparin of inhibiting viral infection. The results are shown in the blue curves in Figure 1B and summarized in Table 1 . In all cases we observed EC 50 in similar ranges. The inhibition assays were completed by standard toxicity tests.
The orange curves in Figure 1B illustrate the results of cell viability studies. In all three cases no toxic effect was observed even at the highest concentrations. We then tested them for irreversible inhibitory activity through virucidal assays. These assays consist of an incubation of the virus and drugs at a concentration corresponding to the EC 90 for a given amount of time and the subsequent evaluation of the residual infectivity of the virus through serial dilutions of the inoculum. It is known 19 that if the effect is solely virustatic, the viral infectivity is fully recovered upon dilution, as we show here for heparin and MES gold NPs against HSV-2 ( Figure   1B ). As expected in both cases we found these particles to have inhibitory activity in the nanomolar range, 16 but virucidal tests showed recovery of the viral infectivity indicating a simple virustatic inhibitory mechanism. If irreversible changes are induced in the virus particle, the infectivity is never regained at all dilutions tested, even though the dilution leads to a final concentration lower than the active dose 22 . MUS:OT-NPs also showed nanomolar inhibition of HSV-2 infectivity but, in contrast to heparin and MES-NPs, no infectivity was regained upon dilution ( Figure 1B) , confirming an irreversible effect (virucidal). In agreement with our hypothesis, all HSPG-binding viruses showed irreversible loss of infectivity when incubated with MUS:OT-NPs, although to differing extents ( Figure 1C ).
The HSV-2 virucidal tests were performed also at different time points, as shown in Figure 1D . While the virustatic effect is immediate, as shown by dose response curve at time 0 h in Supplementary Figure 10 , the virucidal activity develops over time, with the effect being almost complete after 30 min. Indeed, when viruses and MUS:OT-NPs were mixed and immediately added to cells, the inhibitory potency is reduced as compared to the pre-incubation experiment, confirming the time-dependent virucidal effect (Supplementary Figure 10) .
NPs-induction of Irreversible Changes in the Virus Particles
To elucidate the fate of the viruses after NPs binding we performed a series of transmission electron microscopy (TEM) studies on HSV-2 exposed to MUS:OT-NPs and MESNPs. Dry uranyl acetate negatively stained TEM were complemented by cryo-TEM studies (see Supplentary Discussion 2 for the choice of imaging and its validity). 
Ex vivo activity
In order to develop an effective antiviral strategy the active substances have to act mainly after infection. We verified whether MUS:OT-NPs were effective also after virus infection of cells. Cells were infected with wild-type HSV-2 (multiplicity of infection, MOI 0.01 pfu/cell) for 2 h at 37°C. After removal of the viral inoculum, different doses of MUS:OT-NPs were added to the cell monolayers immediately or after 2, 4 or 24h. Cells and supernatants were harvested when the untreated wells exhibited a cytopathic effect of the whole monolayer. The cell free supernatants were then titrated. We determined that MUS:OT-NPs had an EC50 of 4.4 µg/mL, with complete inhibition at 400 µg/mL and 3 logs reduction at 80 µg/mL (Supplementary Figure   17 ) and a relevant inhibition of infection in all the tested time points. Thus the NPs can either prevent infection or block an ongoing infectious process depending on whether they inactivate the virus inoculum or the viral progeny.
To further verify the increased activity of our NPs in a model similar to an in vivo infection, we performed antiviral assays in EpiVaginal tissues. These are composed of humanderived ectocervical epithelial cells grown on a collagen-coated membrane to form a multilayered and highly differentiated tissue that is similar to the vaginal mucosa. We used HSV-2 as a challenge due to its specific tropism for the genital mucosa. HSV-2 (10 5 pfu) was preincubated with the NPs at 500 nM and then added on tissues for 2 h at 37°C. The tissues were washed apically every day and the viral titer was evaluated by titration. The results show a significantly better profile of inhibition of the MUS:OT-NPs compared to the MES-NPs ( Figure   4A ). Moreover we performed experiments in EpiVaginal tissues also pre-treating the tissues for 18 h and subsequently infecting with HSV-2 or infecting the tissue with HSV-2 and treating 24
hpi. In both experiments we could observe a significant inhibition with MUS:OT-NPs (Figure 4 B and C) confirming the preventive and therapeutic activity of MUS:OT-NPs observed in cell lines. Moreover the nanoparticles proved to be non toxic in MTT and LDH assays conducted on
EpiVaginal tissues (Supplementary Figure 18) demonstrating their biocompatibility with a human mucosa.
In vivo activity
To provide the proof of concept that MUS:OT-NPs could exert inhibitory activity also in Moreover, to investigate the biodistribution of MUS:OT-NPs, organ homogeneates were subjected to inductively coupled mass spectrometry (ICP-MS) where it was possible to detect gold presence only in lung homogenates while there was no detectable signal from spleen, liver and brain (Supplementary Figure 19) . Of note, the localization on the MUS:OT-NPs is consistent with their antiviral activity in the lungs as shown in Figure 4D and 4E.
Conclusions
We believe that the approach presented here has a chance to produce medically relevant TEM and Cryo TEM HSV-2 and HPV-PsV (10 5 pfu) were incubated with or without 100 µg/ml Au-NPs and were adsorbed on carbon-and Formvar-coated grids and negatively stained with 0.5% uranyl acetate and observed with CM 10 electron microscope. For cryo TEM, viruses and NPs were flashfrozen in their native hydrated state on carbon coated grids and imaged at -175˚C in a FEI Tecnai F20 Cryo 200kV TEM.
Ex vivo analysis Epivaginal tissues were purchased from Mattek and cultured as indicated by the manufacturer. The tissues were infected with HSV-2 (10 4 -10 5 pfu) and treated with different NPs (500-1500 nM) and titrations of supernatants were conducted on Vero cells to evaluate viral replication.
In vivo analysis Balb/c mice were treated with 200 µg/ml of MUS:OT-NPs and then infected with RSV-Luc as previously described 43 . Luminescence was measured using the IVIS 200 imaging system (Xenogen Corp.).
Statistics
All results are presented as the mean values and sem from three independent experiments. The EC 50 values for inhibition curves were calculated by regression analysis with GraphPad Prism. The selectivity indexes SI were calculated dividing the CC 50 for the EC 50 . A unpaired t-test analysis was performed for virucidal assays and in vivo assays. t values and degrees of freedom (df) are indicated in figure legends. 
